John W Ryder

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
    John W Ryder
    Neuroscience Division, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 319:293-8. 2006
  2. ncbi request reprint Divergent roles of GSK3 and CDK5 in APP processing
    John Ryder
    Neuroscience Discovery Research, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 312:922-9. 2003
  3. ncbi request reprint Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho
    Yan Zhou
    Neuroscience Discovery Research and Bioresearch Technologies and Proteins, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Science 302:1215-7. 2003
  4. doi request reprint Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
    Kenneth W Perry
    Neuroscience Discovery Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropharmacology 55:743-54. 2008

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
    John W Ryder
    Neuroscience Division, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 319:293-8. 2006
    ..Taken together, these data indicate that the cGMP system may play an important role in pharmacological efficacy of the biarylpropylsulfonamide class of AMPA receptor potentiators...
  2. ncbi request reprint Divergent roles of GSK3 and CDK5 in APP processing
    John Ryder
    Neuroscience Discovery Research, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 312:922-9. 2003
    ..Our data support a function for both GSK3 and CDK5 in APP processing, further implicating these two kinases in the pathogenesis of Alzheimer's disease...
  3. ncbi request reprint Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho
    Yan Zhou
    Neuroscience Discovery Research and Bioresearch Technologies and Proteins, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Science 302:1215-7. 2003
    ..Thus, the Rho-Rock pathway may regulate amyloid precursor protein processing, and a subset of NSAIDs can reduce Abeta42 through inhibition of Rho activity...
  4. doi request reprint Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
    Kenneth W Perry
    Neuroscience Discovery Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropharmacology 55:743-54. 2008
    ..High levels of glycine in these brain areas may result in activation of strychnine-sensitive glycine A receptors that are inhibitory on both motor activity and critical brain stem functions such as respiration...